NCT03453164View on ClinicalTrials.gov

Checkpoint Inhibitor and Radiotherapy for Recurrent Gastric Cancer (CIRCUIT)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

March 28, 2018

Primary Completion Date

January 7, 2021

Study Completion Date

January 31, 2021

Conditions
Gastric Cancer
Interventions
RADIATION

Radiotherapy

Radiotherapy of 22.5 Gy/5 fractions/5 days was given to a symptomatic lesion or the largest asymptomatic lesion suitable for irradiation from Day 1.

DRUG

Nivolumab

Nivolumab was administered intravenously starting on Day 15-22 at a dose of 3 mg/kg (body weight) or 240 mg/body every 2 weeks to a total of 6 courses of administration.

Trial Locations (1)

960-1295

Fukushima Medical University Hospital, Fukushima

All Listed Sponsors
lead

Fukushima Medical University

OTHER

NCT03453164 - Checkpoint Inhibitor and Radiotherapy for Recurrent Gastric Cancer (CIRCUIT) | Biotech Hunter | Biotech Hunter